Evolocumab
From Pharmacopedia
More actions
Evolocumab
Repatha
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Hyperlipidemia not at LDL goal on maximally-tolerated statin ± ezetimibe0, Homozygous familial hypercholesterolemia0, Established ASCVD with elevated LDL despite statin (FOURIER trial)0
Pharmacy
Starting dose
140 mg SC every 2 weeks OR 420 mg SC monthly (3 consecutive injections 5 minutes apart due to volume)
Preparations
140 mg/mL single-use prefilled syringe and SureClick autoinjector; Pushtronex 420 mg/3.5 mL on-body infusor
US FDA Max
420 mg/month
Pharmacology
Routes
Subcutaneous
Onset
LDL reduction ~50-60% from baseline at 1-2 weeks
Duration
2-4 weeks per dose
Half-life
~11-17 days[1]
Bioavailability
~72% from SC depot[1]
Pregnancy
Limited data.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Evolocumab is a fully human IgG2 monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9); PCSK9 normally binds the LDL receptor and targets it for lysosomal degradation, so blocking PCSK9 increases hepatic LDL receptor density, accelerates LDL clearance, and lowers serum LDL by ~50-60% on top of statin therapy.0 The FOURIER trial (2017) established cardiovascular event reduction on top of statin therapy, with no apparent floor below which further LDL reduction stopped helping. Cost (~$5,000/year US) and SC injection burden have limited uptake compared with statins[1].
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Repatha (evolocumab), Amgen, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125522s014lbl.pdf